Tag Archives: africanbiobank


MyAfroDNA, an African biotechnology company focused on advancing genomics research and innovation on the African continent, has announced the acquisition and deployment of the MGI CycloneSEQ™ genome sequencer, becoming the first facility in West Africa to deploy this advanced, portable sequencing platform.





CycloneSEQ is a cost-efficient long-read sequencing platform suitable for generating high-quality reference genomes across diverse biological systems. Its accuracy, scalable throughput, and streamlined workflows support reliable genome sequencing, assembly, and variant resolution, enabling large-scale sequencing projects with reduced per-sample cost compared to conventional long-read approaches. The system’s compact footprint and stable operation make it appropriate for sustained deployment in African research environments, facilitating locally led genome projects while strengthening regional capacity and data stewardship.









Figure 1: Photo of recently acquired CycloneSEQ genome sequencer deployed at MyAfroDNA facility in Port Harcourt, Nigeria





The CycloneSEQ™ significantly strengthens MyAfroDNA’s capacity to perform high-resolution, high-accuracy genomic sequencing, enabling applications across human health, agriculture, biodiversity, and environmental research. This milestone marks a major step toward expanding Africa’s ability to generate and analyze genomic data locally, reducing reliance on external sequencing infrastructure.





“The acquisition of the CycloneSEQ™ genome sequencer significantly strengthens our ability to generate high-quality whole-genome data locally and at scale. It allows us to support research across health, agriculture, and biodiversity, while ensuring African-led projects are powered by African infrastructure, expertise, and data ownership,” said Dr. Justin Eze Ideozu, Founder of MyAfroDNA.





Designed for precision and scalability, the CycloneSEQ™ supports whole-genome sequencing, reference genome development, population genomics, and accurate detection of genetic variants. Its flexible workflows enable MyAfroDNA to support both targeted studies and large-scale genomic projects requiring high data quality.





As part of this deployment, MyAfroDNA will immediately begin generating high-quality reference genomes to support biodiversity and conservation genomics in partnership with the African BioGenome Project (AfricaBP) and the West Africa Regional Node of the AfricaBP, Regional Center for Biotechnology and Bioresources Research (RCBBR), University of Port Harcourt, Nigeria.





“The presence of CycloneSEQ™ at MyAfroDNA is a significant development which will certainly inject life into the Endangered and Endemic Species BioGenome Project of the West African Regional node of AfricaBP. It will, as well, facilitate realization of the AfricaBP-10KP 2.0 and AfricaBP Plant Genome Projects. Hopefully, our first genome sequence will be rolled out soon. I sincerely congratulate Dr Justin Eze Ideozu and MyAfroDNA for achieving this great milestone”, said Professor Julian Osuji, AfricaBP West Africa Regional Node Coordinator and Director of the Regional Center for Biotechnology and Bioresources Research (RCBBR), University of Port Harcourt, Nigeria.





“We are happy to see the CycloneSEQ™ deployed in West Africa with MyAfroDNA. This installation represents what MGI aims to achieve globally - democratizing access to advanced sequencing technologies. We look forward to supporting MyAfroDNA and AfricaBP in their mission to sequence Africa’s endemic species by placing high-accuracy long-read capabilities directly into the hands of African researchers", said Chen Fang, General Manager of MGI Europe and Africa.





“MyAfroDNA and MGI are two strong partners of the African BioGenome Project (AfricaBP) who have demonstrated strong commitments to the African genomics and molecular biology landscape. To sequence African indigenous and endemic biological species will require intentional investments by African organisations, and I’m quite pleased (and particularly proud) to see MyAfroDNA take this bold step in acquiring the portable CycloneSEQ genome sequencer. This is a testament to the AfricaBP ecosystem in enabling partnerships, collaborations, and local investments, adding to its progress of consistently provoking local actions. The AfricaBP cannot wait to kickstart its sequencing with MyAfroDNA, and supporting biodiversity genome sequencing in Africa”, said Dr. ThankGod Echezona Ebenezer, Founder and Co-Chair, AfricaBP.





This acquisition positions West Africa as an active contributor to global genomics and life sciences research. By enabling in-region sequencing, MyAfroDNA will support universities, research institutes, conservation organizations, biotechnology companies, and policymakers with access to advanced genomic infrastructure previously unavailable in the region.





This development reinforces MyAfroDNA’s broader mission to strengthen Africa’s biotechnology ecosystem and apply genomics to real-world challenges in health, agriculture, biodiversity conservation, and environmental sustainability.





About MyAfroDNA





We are an African biotechnology company that provides solutions to the significant lack of African representation in clinical, genomics, and translational research. Contact us for questions: info@myafrodna.com 







A recent feature in Nature Africa highlights Tanzania’s remarkable progress in its decades-long battle against neglected tropical diseases (NTDs). Through coordinated mass drug administration, targeted surveillance, and strong community participation, the country has achieved a more than 75% reduction in key NTD infections, including lymphatic filariasis, trachoma, schistosomiasis and onchocerciasis.





This public-health milestone did not happen overnight. It is the result of consistent government investment, cross-sector partnerships, and the active involvement of local health workers who understand the unique cultural and environmental contexts of their communities. Village volunteers have played a crucial role in distributing medicines, tracking cases and ensuring that interventions reach even the most remote populations.The article also highlights that Tanzania’s approach is adaptable. For example, as prevalence levels dropped, the country shifted from broad mass treatment campaigns to more precise surveillance systems, using community data to identify hotspots and allocate resources more efficiently.





This transition demonstrates the power of combining field-driven insights with data-led public-health decision-making.For a company like MyAfroDNA, Tanzania’s progress offers a compelling model for African-led health innovation. It reinforces an essential truth: African health systems are not passive recipients of external interventions. They are active, evidence-driven and capable of delivering measurable, population-level impact when local leadership is centred.These lessons are highly relevant to our molecular-testing, biobanking and biospecimen work.





Sustainable impact in genomics requires:partnerships that elevate community expertise,programmes built on local context rather than imported assumptions, andlong-term models that integrate scientific data with lived realities.Tanzania’s success in reducing NTD burdens is more than a public-health victory. It illustrates what becomes possible when data, community participation and local ownership intersect. As MyAfroDNA advances its African-centred genomics agenda, this achievement reminds us of the responsibility — and opportunity — in supporting African science, strengthening community-driven systems and amplifying homegrown impact.





Read the full article here







The official launch of the African Medicines Agency (AMA) marks a historic turning point for health innovation and pharmaceutical regulation across the continent. Established to streamline the approval and monitoring of medical products, the AMA aims to unify Africa’s fragmented regulatory systems and strengthen the fight against counterfeit or substandard medicines.





According to a recent Nature article, the creation of this central regulatory body promises to improve access to safe, effective, and affordable healthcare solutions. It also paves the way for biotech growth, ensuring that diagnostic tools, vaccines, and molecular testing technologies meet shared standards across African nations. For biotech companies, researchers, and laboratories like MyAfroDNA, this move signals greater collaboration and credibility within global scientific frameworks.





However, the article also points out the challenges ahead. Differences in national policies, limited funding, and uneven political commitment could slow the pace of implementation. To truly succeed, the AMA will require consistent investment in local expertise, capacity building, and transparent governance.





At MyAfroDNA, we see this milestone as an invitation to deepen our role in Africa’s biotechnology ecosystem. As a molecular testing, DNA diagnostics, and biobanking company, our work depends on strong regulatory systems that protect patients and ensure scientific integrity. The AMA’s commitment to standardized, ethical practices aligns perfectly with our mission to make accurate, reliable testing accessible across Africa.





Further reading: What the launch of the African Medicines Agency means for drug and health regulation – Nature (2025)






Explore how MyAfroDNA’s molecular testing and DNA diagnostic services are setting new standards for biospecimen quality and public health in Africa. Visit www.myafrodna.com to learn how we’re advancing Africa’s biotech future, one test at a time.



A new study introduces the South African Blood Regulatory (SABR) resource, a functional genomics dataset derived from >600 individuals from three South Eastern Bantu-speaking populations (Pedi/Bapedi, Tsonga, Zulu). The project integrates whole-genome sequencing and blood transcriptome data to map regulatory variation (expression QTLs / splice QTLs / cell-type interaction QTLs) for 40 blood-cell traits. One major finding: many regulatory variants are unique to individuals of African ancestry, and a substantial fraction are entirely absent in non-African populations.





Compared to the widely used GTEx project (which is heavily biased toward European ancestry), SABR detects more regulatory variants per gene—even though the sample size is smaller. The team also utilizes GWAS summary statistics from African-ancestry participants in the Pan-UK Biobank to demonstrate that SABR enhances the interpretation of genetic associations, specifically identifying putative causal genes and mechanisms linked to blood-related traits and disease risks that would otherwise be more difficult to discern.





SABR’s analysis connects changes in blood cell subtype levels with diseases like HIV, obesity, hypertension, asthma, and the effects of smoking. Several variants that influence disease-relevant cell types or levels are common in SABR but rare or unobserved elsewhere. The full SABR summary statistics are being made publicly available to support researchers.





Read the full article here